U.S., Feb. 14 -- ClinicalTrials.gov registry received information related to the study (NCT06825468) titled 'Role of Hysterectomy in the Treatment of Borderline Ovarian Tumors' on Dec. 30, 2024.
Brief Summary: Borderline ovarian tumors (BOT), are rare epithelial ovarian tumors characterized by the presence of frankly malignant cytologic features in the absence of stromal invasion.
Surgical treatment of perimenopausal and postmenopausal BOT requires bilateral adnexectomy. Although some studies have reported an increased recurrence rate in the group of patients treated with uterine preservation, these data are severely limited by the small sample of patients and the presence of confounding factors in the analysis of oncologic outcomes.
Det...